Kinetics of tumor destruction by chimeric antigen receptor-modified T cells

Molecular Therapy

Volumn 22, Issue 3, 2014, Pages 623-633

  Anurathapan, Usanarat ^a   Chan, Robert C ^a   Hindi, Hakeem F ^a   Mucharla, Roopa ^a   Bajgain, Pradip ^a   Hayes, Brendan C ^a   Fisher, William E ^a   Heslop, Helen E ^a   Rooney, Cliona M ^a   Brenner, Malcolm K ^a   Leen, Ann M ^a   Vera, Juan F ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; MUCIN 1; PROSTATE STEM CELL ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGENIC MODULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; TUMOR ESCAPE;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL- AND TISSUE-BASED THERAPY; HEK293 CELLS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MICE; MUCIN-1; PROSTATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84895500137     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.262     Document Type: Article

References (38)

1. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
2. Kochenderfer, JN, Dudley, ME, Feldman, SA, Wilson, WH, Spaner, DE, Maric, I et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720.
3. Pule, MA, Savoldo, B, Myers, GD, Rossig, C, Russell, HV, Dotti, G et al. (2008). Virusspecific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
4. Till, BG, Jensen, MC, Wang, J, Chen, EY, Wood, BL, Greisman, HA et al. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112: 2261-2271.
5. Jensen, MC, Popplewell, L, Cooper, LJ, DiGiusto, D, Kalos, M, Ostberg, JR et al. (2010). Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16: 1245-1256.
6. Brentjens, RJ, Davila, ML, Riviere, I, Park, J, Wang, X, Cowell, LG et al. (2013). CD19- targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.
7. Jäger, E, Ringhoffer, M, Karbach, J, Arand, M, Oesch, F and Knuth, A (1996). Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66: 470-476.
8. Riker, A, Cormier, J, Panelli, M, Kammula, U, Wang, E, Abati, A et al. (1999). Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126: 112-120.
9. Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
10. Chhieng, DC, Benson, E, Eltoum, I, Eloubeidi, MA, Jhala, N, Jhala, D et al. (2003). MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. Cancer 99: 365-371.
11. Lau, SK, Weiss, LM and Chu, PG (2004). Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol 122: 61-69.
12. Wente, MN, Jain, A, Kono, E, Berberat, PO, Giese, T, Reber, HA et al. (2005). Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 31: 119-125.
13. Mihara, K, Yanagihara, K, Takigahira, M, Kitanaka, A, Imai, C, Bhattacharyya, J et al. (2010). Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. Br J Haematol 151: 37-46.
14. James, SE, Orgun, NN, Tedder, TF, Shlomchik, MJ, Jensen, MC, Lin, Y et al. (2009). Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood 114: 5454-5463.
15. Savoldo, B, Ramos, CA, Liu, E, Mims, MP, Keating, MJ, Carrum, G et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptormodified T cells in lymphoma patients. J Clin Invest 121: 1822-1826.
16. Till, BG, Jensen, MC, Wang, J, Qian, X, Gopal, AK, Maloney, DG et al. (2012). CD20- specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119: 3940-3950.
17. Nakazawa, Y, Huye, LE, Salsman, VS, Leen, AM, Ahmed, N, Rollins, L et al. (2011). PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther 19: 2133-2143.
18. Louis, CU, Savoldo, B, Dotti, G, Pule, M, Yvon, E, Myers, GD et al. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118: 6050-6056.
19. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
20. Porter, DL, Grupp, SA, Kalos, M, Loren, AW, Lledo, L, Gilmore, J et al. (2013). Chimeric antigen receptor T cells directed against CD19 induce durable response and transient cytokine release syndrome in relapsed, refractory CLL and ALL. Blood (ASH annual meeting abstract) No.717.
21. Bollard, CM, Gottschalk, S, Leen, AM, Weiss, H, Straathof, KC, Carrum, G et al. (2007). Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110: 2838-2845.
22. Cruz, CR, Gerdemann, U, Leen, AM, Shafer, JA, Ku, S, Tzou, B et al. (2011). Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res 17: 7058-7066.
23. Goodyear, O, Agathanggelou, A, Novitzky-Basso, I, Siddique, S, McSkeane, T, Ryan, G et al. (2010). Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116: 1908-1918.
24. Brossart, P, Wirths, S, Stuhler, G, Reichardt, VL, Kanz, L and Brugger, W (2000). Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptidepulsed dendritic cells. Blood 96: 3102-3108.
25. Lamers, CH, Sleijfer, S, Vulto, AG, Kruit, WH, Kliffen, M, Debets, R et al. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24: e20-e22.
26. Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM and Rosenberg, SA (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
27. Kloss, CC, Condomines, M, Cartellieri, M, Bachmann, M and Sadelain, M (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31: 71-75.
28. Wilkie, S, van Schalkwyk, MC, Hobbs, S, Davies, DM, van der Stegen, SJ, Pereira, AC et al. (2012). Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 32: 1059-1070.
29. Di Stasi, A, Tey, SK, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
30. Berger, C, Flowers, ME, Warren, EH and Riddell, SR (2006). Analysis of transgenespecific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107: 2294-2302.
31. Sanchez, C, Chan, R, Bajgain, P, Rambally, S, Palapattu, G, Mims, M et al. (2013). Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis 16: 123-31, S1.
32. Katari, UL, Keirnan, JM, Worth, AC, Hodges, SE, Leen, AM, Fisher, WE et al. (2011). Engineered T cells for pancreatic cancer treatment. HPB (Oxford) 13: 643-650.
33. Reiter, RE, Gu, Z, Watabe, T, Thomas, G, Szigeti, K, Davis, E et al. (1998). Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95: 1735-1740.
34. Spicer, AP, Parry, G, Patton, S and Gendler, SJ (1991). Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J Biol Chem 266: 15099-15109.
35. Vera, JF, Brenner, LJ, Gerdemann, U, Ngo, MC, Sili, U, Liu, H et al. (2010). Accelerated production of antigen-specific T cells for preclinical and clinical applications using gaspermeable rapid expansion cultureware (G-Rex). J Immunother 33: 305-315.
36. Sato, N, Fukushima, N, Maitra, A, Matsubayashi, H, Yeo, CJ, Cameron, JL et al. (2003). Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63: 3735-3742.
37. Kohlgraf, KG, Gawron, AJ, Higashi, M, Meza, JL, Burdick, MD, Kitajima, S et al. (2003). Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 63: 5011-5020.
38. Yang, D, Holt, GE, Velders, MP, Kwon, ED and Kast, WM (2001). Murine sixtransmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 61: 5857-5860.